Suchen
Tenax Therapeutics Inc
TENXZur Watchlist hinzufügen
15.460USD
+2.170+16.33%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
375.30MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Tenax Therapeutics Inc Unternehmen
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Tenax Therapeutics Inc Informationen
BörsenkürzelTENX
Name des UnternehmensTenax Therapeutics Inc
IPO-datumOct 28, 1993
CEOGiordano (Christopher T)
Anzahl der mitarbeiter4
WertpapierartOrdinary Share
GeschäftsjahresendeOct 28
Addresse101 Glen Lennox Drive
StadtCHAPEL HILL
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl27517
Telefon19198552100
Websitehttp://www.tenaxthera.com/
BörsenkürzelTENX
IPO-datumOct 28, 1993
CEOGiordano (Christopher T)
Führungskräfte von Tenax Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
12.65K
+39.51%
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Robyn M. Hunter
Ms. Robyn M. Hunter
Independent Director
Independent Director
--
--
Mr. Thomas A. (Tom) Mcgauley
Mr. Thomas A. (Tom) Mcgauley
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
12.65K
+39.51%
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Tenax Therapeutics Inc?
Die fünf größten Anteilseigner von Tenax Therapeutics Inc sind: Dr. Stuart Rich, M.D.
Wie viele Institutionen halten Anteile an Tenax Therapeutics Inc (TENX)?
Mit Stand vom 2026Q1 halten 74 Institutionen Anteile an Tenax Therapeutics Inc, mit einem Gesamtmarktwert von etwa 11.71M, was 51.15% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 5305648.00 gestiegen.